Skip to main content

Advertisement

Table 1 Patient demographics and baseline clinical characteristics by dose level

From: STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Characteristic 2 mg/kg (n = 10) 3 mg/kg (n = 20)
Median age, y (range) 69 (23–83) 65 (22–81)
Male, n (%) 8 (80) 10 (50)
White, n (%) 8 (80) 20 (100)
ECOG performance status, n (%)
 0 4 (40) 3 (15)
 1 6 (60) 15 (75)
 2   2 (10)
Disease stage, n (%)
 I 0 2 (10)
 II 1 (10) 3 (15)
 III 4 (40) 3 (15)
 IV 5 (50) 12 (60)
Prior treatment with radiation therapy, n (%) 3 (30) 6 (30)
Prior treatment with systemic therapy, n (%) 10 (100) 20 (100)
 Median number of prior regimens (range) 4.5 (1–8) 3.5 (1–9)
Prior treatment with surgery, n (%) 3 (30) 3 (15)
History of cancer(s) other than current cancer, n (%) 5 (50) 3 (15)